EID Journal Home > Volume 13, Number 3?March 2007
<!-- InstanceEndEditable --><!-- content_starts_here //--> <!-- InstanceBeginEditable name="Article Content" --> Volume 13, Number 3?March 2007
whole article here :
http://www.cdc.gov/eid/content/13/3/426.htm
Research
Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1
Stephen Mark Tompkins,*<sup>1</sup>
Zi-Shan Zhao,* Chia-Yun Lo,* Julia A. Misplon,* Teresa Liu,* Zhiping Ye,* Robert J. Hogan,? Zhengqi Wu,* Kimberly A. Benton,* Terrence M. Tumpey,? and Suzanne L. Epstein*
*Food and Drug Administration, Bethesda, Maryland, USA; ?University of Georgia, Athens, Georgia, USA; and ?Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Suggested citation for this article
Abstract
Changes in influenza viruses require regular reformulation of strain-specific influenza vaccines. Vaccines based on conserved antigens provide broader protection. Influenza matrix protein 2 (M2) is highly conserved across influenza A subtypes. To evaluate its efficacy as a vaccine candidate, we vaccinated mice with M2 peptide of a widely shared consensus sequence. This vaccination induced antibodies that cross-reacted with divergent M2 peptide from an H5N1 subtype. A DNA vaccine expressing full-length consensus-sequence M2 (M2-DNA) induced M2-specific antibody responses and protected against challenge with lethal influenza. Mice primed with M2-DNA and then boosted with recombinant adenovirus expressing M2 (M2-Ad) had enhanced antibody responses that cross-reacted with human and avian M2 sequences and produced T-cell responses. This M2 prime-boost vaccination conferred broad protection against challenge with lethal influenza A, including an H5N1 strain. Vaccination with M2, with key sequences represented, may provide broad protection against influenza A.
<!-- InstanceEndEditable --><!-- content_starts_here //--> <!-- InstanceBeginEditable name="Article Content" --> Volume 13, Number 3?March 2007
whole article here :
http://www.cdc.gov/eid/content/13/3/426.htm
Research
Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1
Stephen Mark Tompkins,*<sup>1</sup>
Zi-Shan Zhao,* Chia-Yun Lo,* Julia A. Misplon,* Teresa Liu,* Zhiping Ye,* Robert J. Hogan,? Zhengqi Wu,* Kimberly A. Benton,* Terrence M. Tumpey,? and Suzanne L. Epstein**Food and Drug Administration, Bethesda, Maryland, USA; ?University of Georgia, Athens, Georgia, USA; and ?Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Suggested citation for this article
Abstract
Changes in influenza viruses require regular reformulation of strain-specific influenza vaccines. Vaccines based on conserved antigens provide broader protection. Influenza matrix protein 2 (M2) is highly conserved across influenza A subtypes. To evaluate its efficacy as a vaccine candidate, we vaccinated mice with M2 peptide of a widely shared consensus sequence. This vaccination induced antibodies that cross-reacted with divergent M2 peptide from an H5N1 subtype. A DNA vaccine expressing full-length consensus-sequence M2 (M2-DNA) induced M2-specific antibody responses and protected against challenge with lethal influenza. Mice primed with M2-DNA and then boosted with recombinant adenovirus expressing M2 (M2-Ad) had enhanced antibody responses that cross-reacted with human and avian M2 sequences and produced T-cell responses. This M2 prime-boost vaccination conferred broad protection against challenge with lethal influenza A, including an H5N1 strain. Vaccination with M2, with key sequences represented, may provide broad protection against influenza A.
ffice
></o